#$%^&*AU2020201715A120200409.pdf#####Abstract The present invention relates to the provision of a dosing regimen and administration schedule for the use of 1-deoxygalactonojirimycin and enzyme replacement therapy for the treatment of Fabry disease. In an embodiment, the method includes the administration of about 50 mg to about 600 mg of 1-deoxygalactonojirimycin and an effective amount of a-Gal A enzyme replacement therapy to the patient in need thereof.1/15 Period = ERT Alone -0- 2001-003, 1.0 mg/kg + 2017-001, 0.5 mg/kg 350 2018-001, 0.5 mg/kg 3500 -- A-2018-002, 1.0 mg/kg 3000- -v-2018-003, 0.5 mg/kg 2500- + 2018-004, 0.5 mg/kg 2000150010001 500o 0 0 2 4 6 8 10 12 14 16 18 20 22 24 Time (hr) Period = Co-Administration -0-2001-003, 1.0 mg/kg+AT1001 150 mg 3-+ 2017-001, 0.5 mg/kg+AT1001 150 mg E+2017-001,0.5mg/kg+AT1001150mg 3500 -2018-001, 0.5 mg/kg+AT1001 150 mg 3500--2018-002, 1.0 mg/kg+AI1001 150 mg 3000- -w-2018-003, 0.5 mg/kg+AT1001 150 mg 2500- +2018-004, 0.5 mg/kg+AT1001 150 mg 200015001000500 0 E 0 2 4 6 8 10 12 14 16 18 20 22 24 Time (hr) FIG. 1
